GLP-1 Receptor Agonists Significantly Reduce BMI and HbA1c in Pediatric Obesity and Type 2 Diabetes
Background
The rising prevalence of childhood obesity and youth-onset type 2 diabetes mellitus (T2DM) presents a significant public health challenge, often requiring more than lifestyle interventions and metformin. Current treatment options for these conditions in pediatric populations are limited, creating a critical gap for effective pharmacological adjuncts. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated substantial efficacy in adults for weight management and glycemic control by activating the GLP-1R, making them a promising avenue for investigation in younger patients. This systematic review synthesizes existing evidence on their utility in pediatric populations.
Study Design
This systematic review evaluated the efficacy and safety of GLP-1 RAs in children and adolescents aged 6 to <18 years with obesity or T2DM. Researchers systematically reviewed PubMed-indexed studies published from 2000 to 2025, identifying seven pivotal randomized controlled trials and six meta-analyses. The review synthesized data from a total of 901 participants, focusing on primary endpoints such as BMI reduction, HbA1c improvement, and the incidence of adverse events, comparing GLP-1 RA interventions against placebo or standard care in the included studies.
Results
GLP-1 RAs demonstrated significant efficacy in both pediatric obesity and T2DM. In adolescents with obesity, semaglutide 2.4 mg/week produced the greatest BMI reduction. Following this, liraglutide 3.0 mg/day also significantly improved BMI SDS in both adolescents and younger children. For youth-onset T2DM, liraglutide 1.8 mg/day and dulaglutide significantly improved HbA1c compared with placebo. Weight-reducing agents additionally improved insulin resistance and modestly reduced triglycerides, while changes in LDL-cholesterol were minimal. Gastrointestinal adverse events, primarily nausea and vomiting, were the most frequent, generally transient, and dose-dependent. No significant adverse effects on linear growth or pubertal progression were reported across the reviewed studies.
Semaglutide 2.4 mg/week was identified as providing the greatest BMI reduction in adolescents with obesity among the GLP-1 RAs studied.
Key Findings
- Semaglutide 2.4 mg/week achieved the greatest BMI reduction in adolescents with obesity.
- Liraglutide 3.0 mg/day improved BMI SDS in adolescents and younger children with obesity.
- Liraglutide 1.8 mg/day and dulaglutide significantly improved HbA1c in youth-onset T2DM.
- GLP-1 RAs improved insulin resistance and modestly reduced triglycerides.
- Gastrointestinal adverse events (nausea, vomiting) were common, transient, and dose-dependent.
Why It Matters
This comprehensive review solidifies the role of GLP-1 RAs as effective adjuncts for managing pediatric obesity and youth-onset T2DM, offering crucial pharmacological support beyond lifestyle changes and metformin. For clinicians, this means GLP-1 RAs can be considered as a viable treatment option for eligible pediatric patients, potentially altering current prescribing guidelines. While short-to-medium term safety appears favorable, the review underscores the critical need for longer-term studies to fully assess cardiovascular safety, bone health, and growth outcomes in this vulnerable population. This insight is vital for informing future clinical protocols and ensuring the safe, sustained use of these powerful metabolic agents in younger individuals.
glp-1-ra
semaglutide
liraglutide
dulaglutide
pediatric-obesity
type-2-diabetes